Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal women

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy, safety, and quality of life (QOL) data when available, of adjuvant third-generation AIs (anastrozole, letrozole, exemestane) compared to tamoxifen or placebo in postmenopausal women with early stage hormone receptor-positive breast cancer.